ER-α36 Cancer Research Results

ER-α36, estrogen receptor alpha (ERα) protein variant: Click to Expand ⟱
Source:
Type:
ER-α36 is a variant of the estrogen receptor alpha (ERα) protein. It is a truncated form of the full-length ERα protein.
ER-α36 is overexpressed in certain types of breast cancer, including triple-negative breast cancer (TNBC) and tamoxifen-resistant breast cancer. ER-α36 has been found to promote cell proliferation, migration, and invasion in breast cancer cells, contributing to tumor progression and metastasis. The expression of ERα is a significant factor in the prognosis of various cancers, particularly in breast and endometrial cancers, where it is a key target for therapy. The relationship between ERα expression and prognosis can vary widely among different cancer types, and ongoing research is essential to fully understand its role in cancer biology and treatment response.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
2751- BetA,    Betulinic acid inhibits proliferation and triggers apoptosis in human breast cancer cells by modulating ER (α/β) and p53
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
tumCV↓, ER-α36↓,
687- EGCG,    Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
ER-α36↓,
935- Gallo,    Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
LDH↓, ROS↑, TumCP↓, Glycolysis↓, ATP↓, ER-α36↓, Apoptosis?,
1234- Gra,    Graviola attenuates DMBA-induced breast cancer possibly through augmenting apoptosis and antioxidant pathway and downregulating estrogen receptors
- in-vivo, BC, NA
Apoptosis↑, BAX↑, P53↑, Casp3↑, ER-α36↓, lipid-P↓,
1494- SFN,  doxoR,    Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model
- in-vivo, BC, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
CardioT↓, *GSH↑, *ROS↓, *NRF2↑, NRF2∅, HDAC↓, DNMTs↓, Casp3↑, ER-α36↓, Remission↑, eff↑, ROS↑, selectivity?,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

lipid-P↓, 1,   NRF2∅, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   LDH↓, 1,  

Cell Death ⓘ

Apoptosis?, 1,   Apoptosis↑, 1,   BAX↑, 1,   Casp3↑, 2,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

DNA Damage & Repair ⓘ

DNMTs↓, 1,   P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,  

Migration ⓘ

ER-α36↓, 5,   TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   selectivity?, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  

Functional Outcomes ⓘ

CardioT↓, 1,   Remission↑, 1,  
Total Targets: 21

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   NRF2↑, 1,   ROS↓, 1,  
Total Targets: 3

Scientific Paper Hit Count for: ER-α36, estrogen receptor alpha (ERα) protein variant
1 Betulinic acid
1 EGCG (Epigallocatechin Gallate)
1 Galloflavin
1 Graviola
1 Sulforaphane (mainly Broccoli)
1 doxorubicin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:843  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page